Trials / Terminated
TerminatedNCT03463161
Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy
A Phase II Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to determine response rate of the combination of pembrolizumab plus epacadostat in patients with head and neck cancers that have received prior immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab (200mg/kg) given by intravenous infusion every 3 weeks. |
| DRUG | Epacadostat | Epacadostat (100mg) taken by mouth twice a day. |
Timeline
- Start date
- 2018-03-23
- Primary completion
- 2018-12-04
- Completion
- 2018-12-04
- First posted
- 2018-03-13
- Last updated
- 2020-01-27
- Results posted
- 2020-01-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03463161. Inclusion in this directory is not an endorsement.